Keros Therapeutics vs Arcus Biosciences
Arcus Biosciences reported revenue of $247 million in fiscal 2025, about the same as Keros Therapeutics' $244 million in fiscal 2025. Keros Therapeutics had an operating margin of 27.7%, against -156.3% at Arcus Biosciences. Free cash flow was $106 million at Keros Therapeutics and −$484 million at Arcus Biosciences.
Side by side
| Keros Therapeutics | Arcus Biosciences | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $244M | $247M |
| Revenue growth | — | −4.3% |
| Revenue growth a year, last 5 years | — | 25.9% |
| Gross margin | — | — |
| Operating margin | 27.7% | −156.3% |
| Net margin | 35.7% | −142.9% |
| Free cash flow | $106M | −$484M |
| Free cash flow margin | 43.5% | −195.9% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $375M | $0M |
| Change in diluted share count | 1.1% | 19.2% |
| Last close | $11.39 | $15.78 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $75,770, sold $506,996 | sold $9.0 million |
| Piotroski F-score | — | 0 of 8 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Keros TherapeuticsArcus Biosciences
Operating margin
Percent of revenue
Keros TherapeuticsArcus Biosciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Keros TherapeuticsArcus Biosciences
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Keros Therapeutics and Arcus Biosciences pages.